EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Inclusion Criteria :

• At least 18 years old at time of consent

• Signed and dated written informed consent in accordance with ICH-GCP and locallegislation prior to admission to the trial

• Women of childbearing potential (WOCBP) must be ready and able to use highlyeffective methods of birth control per ICH M3 (R2).

• Participants with medical history of hypertension and on active pharmacologicaltreatment

• Participants with medical history of type 2 diabetes mellitus (T2DM) and on activepharmacological treatment

• Established cardiovascular (CV) disease and on active pharmacological treatment

• At least one additional risk factor for developing heart failure (HF)

Exclusion Criteria:

• History of HF or hospitalization for HF or treatment of HF

• Atrial fibrillation or Atrial flutter with a resting heart rate >110 beats perminute (bpm) documented by echocardiogram (ECG) at Visit 1 (screening)

• Advanced untreated conduction disease or untreated clinically relevant ventriculararrhythmia at Visit 1 (screening)

• Treatment with an Mineralocorticoid receptor antagonist (MRA)

• Treatment with amiloride or other potassium-sparing diuretic

• Receiving the following treatments at Visit 1 (screening) or requiring suchtreatment before Visit 2 (randomisation), or planned during the trial:

• A direct renin inhibitor (e.g. aliskiren)

• More than one Angiotensin-converting enzyme inhibitor (ACEi) and/or Angiotensinreceptor blocker (ARB) (including Angiotensin receptor-neprilysin inhibitor (ARNi)) used simultaneously

• Other aldosterone synthase inhibitors (e.g. baxdrostat)

• Systemic mineralocorticoid replacement therapy (e.g. fludrocortisone) Furtherexclusion criteria apply.